Due to Mdm2 deregulation has been reported in various tumor types, Nutlin-3 has been an option to block the p53-binding site of MDM2 competitively and induce the upregulation and activation of p53 pathway (Yee-Lin et al., 2018). The gene discussed is TP53; the disease is neoplasm.